Aurinia’s only project is due in front of the FDA, and outcomes are expected for Merck KGaA, Bayer and Merck & Co.
A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.
Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.
Deals were a major driver of mid-cap share movement in the first quarter, but pipeline progress and misfires played their parts too.